CD19 and precursor B-cell acute lymphoblastic leukemia: KTE-X19 (brexucabtagene autoleucel), another FDA-approved CD19 CAR T-cell therapy, reports a CR/CRi rate of 71% in R/R adult B-ALL patients [20].